HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Neuroepithelial Neoplasms (Gliomatosis Cerebri)

Subscribe to New Research on Neuroepithelial Neoplasms

Neoplasms composed of neuroepithelial cells, which have the capacity to differentiate into NEURONS, oligodendrocytes, and ASTROCYTES. The majority of craniospinal tumors are of neuroepithelial origin. (From Dev Biol 1998 Aug 1;200(1):1-5)

Also Known As:

Gliomatosis Cerebri; Neoplasms, Neuroepithelial; Neuroepithelial Tumors; Astroblastomas; Ependymoastrocytomas; Neoplasm, Neuroepithelial; Neuroepithelial Neoplasm; Neuroepithelial Tumor; Polar Spongioblastoma; Polar Spongioblastomas; Spongioblastomas, Polar; Tumor, Neuroepithelial; Tumors, Neuroepithelial; Astroblastoma; Ependymoastrocytoma; Spongioblastoma, Polar

Networked: 297 relevant articles (11 outcomes, 27 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neuroepithelial Neoplasms (Gliomatosis Cerebri)
2.	Glioma (Gliomas)
3.	Seizures (Seizure)
4.	Malformations of Cortical Development
5.	Venous Thromboembolism

Experts

1.	Suh, Yeon-Lim: 5 articles (11/2015 - 11/2005)
2.	Chen, Li: 5 articles (03/2010 - 07/2005)
3.	Sanson, M: 4 articles (08/2009 - 07/2004)
4.	Seo, Dae Won: 4 articles (06/2008 - 08/2003)
5.	Hong, Seung Bong: 4 articles (06/2008 - 08/2003)
6.	Santi, Mariarita: 3 articles (03/2015 - 07/2010)
7.	Biegel, Jaclyn A: 3 articles (03/2015 - 07/2010)
8.	Harding, Brian N: 3 articles (03/2015 - 11/2003)
9.	Figarella-Branger, Dominique: 3 articles (09/2013 - 02/2003)
10.	Wang, Yin: 3 articles (08/2013 - 05/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Neuroepithelial Neoplasms:

1.	temozolomide (Temodar)FDA LinkGeneric 11/27/2001 - "Possible efficacy of temozolomide in a patient with gliomatosis cerebri." 02/19/2008 - "Up-front temozolomide (TMZ) has been recently proposed as a treatment for gliomatosis cerebri (GC), but no predictive or prognostic markers have been identified so far. " 12/01/2003 - "Response to low dose temozolomide in radiation induced gliomatosis cerebri." 11/01/2003 - "A 46-year-old man with gliomatosis cerebri was treated with temozolomide (200 mg/m(2) per day for 5 days every 28 days). " 11/01/2003 - "Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration."
2.	2,6-dinitrotoluene (DNT)IBA 08/01/2012 - "To study the clinicopathologic features, radiologic findings, treatment options and prognosis of dysembryoplastic neuroepithelial tumor (DNT). " 08/01/2007 - "To study the clinicopathologic features, immunophenotype and histogenesis of dysembryoplastic neuroepithelial tumor (DNT). " 09/01/2005 - "To study the clinicopathologic features and radiologic findings of dysembryoplastic neuroepithelial tumor (DNT). " 09/01/2005 - "OBJECTIVE To study the clinicopathologic features, radiologic findings, treatment modalities and prognosis of dysembryoplastic neuroepithelial tumor (DNT). " 01/01/1999 - "Dysembryoplastic neuroepithelial tumor (DNT): an ultrastructural study of six cases."
3.	Procarbazine (Matulane)FDA Link 09/01/2011 - "NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri." 01/01/2008 - "Procarbazine and CCNU as initial treatment in gliomatosis cerebri." 09/01/2011 - "The NOA-05 multicenter trial was performed to analyze the efficacy of primary chemotherapy with procarbazine and lomustine (PC) in patients with gliomatosis cerebri (GC) and to define clinical, imaging, and molecular factors influencing outcome. " 10/01/2014 - "Procarbazine, CCNU, and Vincristine Chemotherapy in Gliomatosis Cerebri." 10/01/2002 - "We conclude that (1) the molecular genetic alterations in gliomatosis cerebri resemble those in diffuse astrocytomas; (2) the prognosis of gliomatosis cerebri is variable but for at least 50% of patients as poor as for glioblastoma; and (3) some patients respond to radiotherapy and/or procarbazine, carmustine, vincristine chemotherapy."
4.	Lomustine (CCNU)FDA Link 09/01/2011 - "NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri." 01/01/2008 - "Procarbazine and CCNU as initial treatment in gliomatosis cerebri." 09/01/2011 - "The NOA-05 multicenter trial was performed to analyze the efficacy of primary chemotherapy with procarbazine and lomustine (PC) in patients with gliomatosis cerebri (GC) and to define clinical, imaging, and molecular factors influencing outcome. " 10/01/2014 - "Procarbazine, CCNU, and Vincristine Chemotherapy in Gliomatosis Cerebri."
5.	Methionine (L-Methionine)FDA Link 10/01/2014 - "Accuracy of distinguishing between dysembryoplastic neuroepithelial tumors and other epileptogenic brain neoplasms with [¹¹C]methionine PET." 01/01/2004 - "Usefulness of [11C]methionine PET in the diagnosis of dysembryoplastic neuroepithelial tumor with temporal lobe epilepsy." 01/01/2004 - "We assessed the diagnostic value of [11C]methionine (MET) positron emission tomography (PET) in the differential diagnosis of dysembryoplastic neuroepithelial tumors (DNETs) among benign tumors associated with temporal lobe epilepsy (TLE). " 02/01/2011 - "¹¹C-Methionine or ¹¹C-Choline PET is superior to MRI in the evaluation of gliomatosis cerebri." 10/01/1999 - "Positron emission tomography using [18F] fluorodeoxyglucose and [11C] l-methionine to metabolically characterize dysembryoplastic neuroepithelial tumors."
6.	Choline (Choline Chloride)IBA 02/01/2011 - "¹¹C-Methionine or ¹¹C-Choline PET is superior to MRI in the evaluation of gliomatosis cerebri." 01/01/2004 - "A patient with histologically proven gliomatosis cerebri presented with a normal choline level but a markedly abnormal elevated myo-inositol level on magnetic resonance (MR) spectroscopy. " 01/01/2004 - "Role of proton magnetic resonance spectroscopy in the diagnosis of gliomatosis cerebri: a unique pattern of normal choline but elevated Myo-inositol metabolite levels." 05/01/2003 - "Proton MR spectroscopy of gliomatosis cerebri: case report of elevated myoinositol with normal choline levels." 05/01/2003 - "The primary conclusion is that in suspected cases of gliomatosis cerebri, myo-inositol/creatine and myo-inositol/N-acetyl should be determined because they may provide evidence of tumor, even though choline/creatine is normal. "
7.	fibrin fragment D (D-dimer)IBA 02/01/2011 - "The combination of sequential serum D-dimer measurement and Doppler ultrasonography of the lower extremity is an efficient and non-invasive procedure for identifying asymptomatic VTE in patients with neuroepithelial tumor." 02/01/2011 - "The efficacy of combined serum D-dimer level measurement and Doppler ultrasonography of the lower extremity was investigated for screening of venous thromboembolism (VTE) in patients with neuroepithelial tumor. " 02/01/2011 - "Early detection of venous thromboembolism in patients with neuroepithelial tumor: efficacy of screening with serum D-dimer measurements and Doppler ultrasonography."
8.	DNA (Deoxyribonucleic Acid)IBA 03/01/1995 - "Dysembryoplastic neuroepithelial tumor: morphological, immunocytochemical, and deoxyribonucleic acid analyses in a pediatric series." 07/09/1991 - "We therefore suggest that the flow cytometric measurement of DNA-ploidy has relevant significance in predicting survival in patients treated for intracranial neuroepithelial tumors." 07/09/1991 - "Prognostic significance of nuclear DNA content in human neuroepithelial tumors." 04/30/1988 - "The prognostic value of proliferative activity and DNA distribution (ploidy), determined by flow cytometry (FCM), was evaluated in 38 cases of human malignant neuroepithelial tumors. " 07/09/1991 - "The relationship between survival and flow cytometric DNA-ploidy and other prognostic factors such as histological subtype, anatomical tumor site, patient sex and age was investigated in 153 patients with intracranial neuroepithelial tumors who underwent surgical treatment. "
9.	AntibodiesIBA 02/01/2004 - "In summary, the use of immunohistochemistry using Olig1 antibodies alone or in combination with anti-GFAP antibody, which can be performed in the routine diagnostic setting, may help in the diagnosis of neuroepithelial tumors." 03/01/1983 - "Neuroepithelial neoplasms of childhood were examined immunohistochemically using antibodies against a neurofilament polypeptide and glial fibrillary acidic protein. " 03/01/1993 - "Since some monoclonal anti-cytokeratin antibodies also react with glial tumors to a relatively high degree, an immunohistochemical study was performed to examine the reaction of 40 glial tumors and neuroepithelial tumors with glial differentiation to the monoclonal anti-epithelial non-cytokeratin antibodies HEA 125 and Ber EP4. " 03/01/2008 - "Discussion concentrates on the use of 4 antibodies: BAF47 in the diagnosis of atypical teratoid/ rhabdoid tumor, OCT4 in intracranial germinoma, beta-catenin in craniopharyngioma, and NeuN as a marker of neuronal differentiation in neuroepithelial neoplasms." 03/01/2010 - "Herein, we characterized the cellular interface between the tumor and the surrounding brain tissue in 48 CP (41 adaCP and seven papCP) compared to non-neuroepithelial tumors, i.e., 12 cavernous hemangiomas, 10 meningiomas, and 14 metastases using antibodies directed against glial fibrillary acid protein (GFAP), vimentin, nestin, microtubule-associated protein 2 (MAP2) splice variants, and tenascin-C. "
10.	Vincristine (Oncovin)FDA LinkGeneric 10/01/2014 - "Procarbazine, CCNU, and Vincristine Chemotherapy in Gliomatosis Cerebri." 09/01/2007 - "In this study, we tested the chemosensitivities of malignant neuroepithelial tumors (26 glioblastomas, 9 anaplastic astrocytomas, and 5 MBs) to etoposide and vincristine using the succinate dehydrogenase inhibition test and found that MB cells are more sensitive to etoposide and more resistant to vincristine than other tumor cells. " 10/01/2002 - "We conclude that (1) the molecular genetic alterations in gliomatosis cerebri resemble those in diffuse astrocytomas; (2) the prognosis of gliomatosis cerebri is variable but for at least 50% of patients as poor as for glioblastoma; and (3) some patients respond to radiotherapy and/or procarbazine, carmustine, vincristine chemotherapy."

Therapies and Procedures

1.	Radiotherapy 09/01/2014 - "This study showed that gliomatosis cerebri could be effectively treated with radiotherapy and that initial response to radiotherapy was a significant prognostic factor affecting the survival." 09/01/2014 - "To evaluate the efficacy of radiotherapy and factors affecting the prognosis of gliomatosis cerebri. " 07/15/2003 - "Gliomatosis cerebri: improved outcome with radiotherapy." 07/15/2003 - "In this study, we sought to assess the role of radiotherapy (RT) and identify prognostic factors in gliomatosis cerebri. " 03/01/2015 - "Gliomatosis cerebri having a poor performance status without recurrence after radiotherapy: a single institutional experience."
2.	Drug Therapy (Chemotherapy) 07/27/2004 - "The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known. " 07/27/2004 - "Initial chemotherapy is useful for some patients with gliomatosis cerebri. " 07/27/2004 - "Initial chemotherapy in gliomatosis cerebri." 06/01/2004 - "Combined surgery, radiation, and chemotherapy for oligodendroglial gliomatosis cerebri." 08/12/2003 - "Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri."
3.	Adjuvant Chemotherapy 01/01/2010 - "Impact of adjuvant chemotherapy for gliomatosis cerebri." 10/01/1993 - "Surgery, hyperfractionated craniospinal irradiation, and adjuvant chemotherapy in the management of supratentorial embryonal neuroepithelial neoplasms in children."
4.	Decompression 04/01/2013 - "Uncal decompression in gliomatosis cerebri." 01/01/2003 - "Posterior fossa decompression for life-threatening tonsillar herniation in patients with gliomatosis cerebri: report of three cases."
5.	Hemispherectomy 10/01/2011 - "This is a rare case report of a congenital gliomatosis cerebri WHO grade III, treated with partial hemispherectomy, leading to a good clinical and neurological long-term outcome." 10/01/2011 - "[Neonatal intracerebral bleeding as initial symptom of gliomatosis cerebri WHO III--neurological outcome after partial hemispherectomy]."